Ecolab Delivers Very Strong First Quarter Operating Performance; Reported Diluted EPS $0.82; Adjusted Diluted EPS $0.88, +7%; Continue to Expect Further Performance Improvement Through 2023
-
Reported sales
, +$3.6 billion 9% versus last year. Organic sales +13% , led by double-digit growth in the Institutional & Specialty, Industrial, and Other segment, and improved growth in the Healthcare & Life Sciences segment. -
Reported operating income +
38% . Organic operating income growth accelerated to +19% , as continued strong pricing and productivity gains more than offset easing but ongoing delivered product cost inflation and challenging macroeconomic conditions. -
Reported operating income margin
9.8% . Organic operating income margin10.6% , +50 bps versus last year, reflecting modest gross margin expansion and improved productivity. -
Reported diluted EPS
, +$0.82 37% . Adjusted diluted EPS, excluding special gains and charges and discrete tax items were , +$0.88 7% . Currency translation and higher interest expense had a combined per share unfavorable impact on first quarter EPS.$0.11
2023 OUTLOOK
- 2023: Ecolab continues to expect to deliver quarterly adjusted earnings per share growth that accelerates towards its low double-digit historical performance.
-
2Q 2023: Expect second quarter 2023 adjusted diluted earnings per share in the
to$1.15 range, +5 to$1.25 14% versus last year.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
First Quarter Ended March 31 |
||||||||||||||||||||
|
Reported |
|
|
|
|
Adjusted |
|
|
|
||||||||||||
(unaudited) |
Public Currency Rates |
|
% |
|
Public Currency Rates |
|
% |
||||||||||||||
(millions, except per share) |
2023 |
|
2022 |
|
Change |
|
|
2023 |
|
|
2022 |
|
Change |
||||||||
Net sales |
$ |
3,571.6 |
|
|
$ |
3,266.7 |
|
|
9 |
% |
|
$ |
3,571.6 |
|
|
$ |
3,266.7 |
|
|
9 |
% |
Operating income |
|
351.6 |
|
|
|
254.5 |
|
|
38 |
% |
|
|
379.3 |
|
|
|
331.5 |
|
|
14 |
% |
Net income attributable to Ecolab |
|
233.4 |
|
|
|
171.9 |
|
|
36 |
% |
|
|
250.5 |
|
|
|
236.5 |
|
|
6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted earnings per share attributable to Ecolab |
$ |
0.82 |
|
|
$ |
0.60 |
|
|
37 |
% |
|
$ |
0.88 |
|
|
$ |
0.82 |
|
|
7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Organic |
|
% |
|
|
|
|
|
|
|
|
|
|||||||||
|
2023 |
|
2022 |
|
Change |
|
|
|
|
|
|
|
|
|
|||||||
Net sales |
$ |
3,533.8 |
|
|
$ |
3,137.7 |
|
|
13 |
% |
|
|
|
|
|
|
|
|
|
||
Operating income |
|
376.1 |
|
|
|
315.5 |
|
|
19 |
% |
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CEO Comment
Christophe Beck, Ecolab’s chairman and chief executive officer, said, “We had a very strong start to 2023 with our team delivering continued double-digit organic sales growth, consistent with our expectations. We continued taking steps to further strengthen our growth foundation, like making investments in our Life Sciences business to capitalize on its long-term growth opportunities. Overall, our efforts drove organic operating income margin expansion with continued strong pricing and further productivity gains, in addition to easing but ongoing inflationary headwinds. This excellent performance resulted in
“Looking ahead, we are well positioned to build on our operating momentum and expect further performance improvement in 2023. While the macroeconomic headwinds and inflationary pressures are expected to persist, our focus remains on offense – driving robust sales growth as we leverage our leading customer value proposition and our innovation pipeline, as well as on capturing our significant operating margin expansion opportunity. As a result, we continue to anticipate strong organic sales gains, double-digit growth in organic operating income, and adjusted earnings per share growth that accelerates towards our low double-digit historical performance.”
First Quarter 2023 Consolidated Results
Ecolab’s first quarter reported sales increased
First quarter 2023 reported operating income increased
Reported other income decreased
Reported interest expense increased
The reported income tax rate for the first quarter of 2023 was
Reported net income increased
Reported diluted earnings per share increased
First Quarter 2023 Segment Review
|
|
|
|
|
|
|
|
|
|
|
|
||
Global Industrial |
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
||
(unaudited) |
First Quarter Ended March 31 |
|
|
|
|
Organic |
|||||||
(millions) |
2023 |
|
2022 |
|
% Change |
|
% Change |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
||
Fixed currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
1,699.3 |
|
|
$ |
1,511.4 |
|
|
12 |
% |
|
12 |
% |
Operating income |
|
215.6 |
|
|
|
179.9 |
|
|
20 |
% |
|
20 |
% |
Operating income margin |
|
12.7 |
% |
|
|
11.9 |
% |
|
|
|
|
|
|
Organic operating income margin |
|
12.7 |
% |
|
|
11.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Public currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
1,709.4 |
|
|
$ |
1,565.7 |
|
|
9 |
% |
|
|
|
Operating income |
|
217.7 |
|
|
|
191.1 |
|
|
14 |
% |
|
|
|
The Industrial segment includes Water, Food & Beverage, and Paper |
Effective January 1, 2023, the Company’s former Downstream operating segment is now part of the Water operating segment. This change did not have any impact on the Global Industrial reportable segment. |
|
|
|
|
|
|
|
|
|
|
|
|
||
Global Institutional & Specialty |
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
||
(unaudited) |
First Quarter Ended March 31 |
|
|
|
|
Organic |
|||||||
(millions) |
2023 |
|
2022 |
|
% Change |
|
% Change |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
||
Fixed currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
1,126.6 |
|
|
$ |
991.3 |
|
|
14 |
% |
|
14 |
% |
Operating income |
|
125.7 |
|
|
|
108.6 |
|
|
16 |
% |
|
16 |
% |
Operating income margin |
|
11.2 |
% |
|
|
11.0 |
% |
|
|
|
|
|
|
Organic operating income margin |
|
11.2 |
% |
|
|
11.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Public currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
1,128.8 |
|
|
$ |
1,009.4 |
|
|
12 |
% |
|
|
|
Operating income |
|
125.9 |
|
|
|
110.9 |
|
|
14 |
% |
|
|
|
The Institutional & Specialty segment includes Institutional and Specialty |
Organic sales growth accelerated to
|
|
|
|
|
|
|
|
|
|
|
||||
Global Healthcare & Life Sciences |
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
(unaudited) |
|
First Quarter Ended March 31 |
|
|
|
Organic |
||||||||
(millions) |
2023 |
|
2022 |
|
% Change |
|
% Change |
|||||||
|
|
|
|
|
|
|
|
|
|
|
||||
Fixed currency |
|
|
|
|
|
|
|
|
|
|
||||
Sales |
|
$ |
378.6 |
|
|
$ |
348.2 |
|
|
9 |
% |
|
9 |
% |
Operating income |
|
|
35.0 |
|
|
|
41.9 |
|
|
(16 |
)% |
|
(16 |
)% |
Operating income margin |
|
|
9.2 |
% |
|
|
12.0 |
% |
|
|
|
|
||
Organic operating income margin |
|
|
9.2 |
% |
|
|
12.0 |
% |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
||||
Public currency |
|
|
|
|
|
|
|
|
|
|
||||
Sales |
|
$ |
379.7 |
|
|
$ |
362.8 |
|
|
5 |
% |
|
|
|
Operating income |
|
|
35.2 |
|
|
|
44.3 |
|
|
(21 |
)% |
|
|
The Healthcare & Life Sciences segment includes Healthcare and Life Sciences |
Organic sales grew
|
|
|
|
|
|
|
|
|
|
|
|
||
Other |
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
||
(unaudited) |
First Quarter Ended March 31 |
|
|
|
|
Organic |
|||||||
(millions) |
2023 |
|
2022 |
|
% Change |
|
% Change |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
||
Fixed currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
329.3 |
|
|
$ |
286.8 |
|
|
15 |
% |
|
15 |
% |
Operating income |
|
50.1 |
|
|
|
37.1 |
|
|
35 |
% |
|
35 |
% |
Operating income margin |
|
15.2 |
% |
|
|
12.9 |
% |
|
|
|
|
|
|
Organic operating income margin |
|
15.2 |
% |
|
|
12.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Public currency |
|
|
|
|
|
|
|
|
|
|
|
||
Sales |
$ |
330.0 |
|
|
$ |
294.0 |
|
|
12 |
% |
|
|
|
Operating income |
|
50.2 |
|
|
|
37.9 |
|
|
32 |
% |
|
|
|
The Other segment includes Pest Elimination, Textile Care and Colloidal Technologies |
Organic sales growth accelerated to
|
|
|
|
|
|
|
|||
Corporate |
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
(unaudited) |
|
First Quarter Ended March 31 |
|||||||
(millions) |
|
2023 |
|
2022 |
|||||
|
|
|
|
|
|
|
|||
Public currency |
|
|
|
|
|
|
|||
Sales |
|
$ |
23.7 |
|
|
|
$ |
34.8 |
|
|
|
|
|
|
|
|
|||
Corporate operating expense |
|
|
|
|
|
|
|||
Nalco and Purolite amortization |
|
|
50.2 |
|
|
|
|
52.7 |
|
Special (gains) and charges |
|
|
27.7 |
|
|
|
|
77.0 |
|
Other |
|
|
(0.5 |
) |
|
|
|
- |
|
Total Corporate operating expense |
|
$ |
77.4 |
|
|
|
$ |
129.7 |
|
First quarter of 2023 corporate segment includes:
-
sales of
to ChampionX under the Master Cross Supply and Product Transfer agreements Ecolab entered into as part of the ChampionX separation$24 million -
amortization expense of
related to the Nalco merger intangible assets and$29 million related to Purolite acquisition intangible assets$21 million -
special gains and charges were a net charge of
, primarily related to restructuring costs$28 million
Special gains and charges for the first quarter of 2022 were a net charge of
Business Outlook
2023
Ecolab continues to expect to deliver performance that improves despite a challenging macro environment characterized by high delivered product costs and easing demand. In addition, higher interest expense and currency translation are estimated to have a combined
The Company expects double-digit growth in organic operating income, driven by continued robust sales growth, easing delivered product cost inflation, and improved productivity. This strong performance is expected to more than overcome the challenging environment to deliver quarterly adjusted earnings per share growth that accelerates towards our low double-digit historical performance.
2023 – Second Quarter
Ecolab expects second quarter 2023 adjusted diluted earnings per share in the
The Company currently expects quantifiable special charges in the second quarter of 2023 to be approximately
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of
Ecolab will host a live webcast to review the first quarter earnings announcement today at 1:00 p.m. Eastern Time. The webcast, along with related materials, will be available to the public on Ecolab's website at www.ecolab.com/investor. A replay of the webcast and related materials will be available at that site.
Cautionary Statements Regarding Forward-Looking Information
This news release contains certain statements relating to future events and our intentions, beliefs, expectations and predictions for the future which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project,” “may,” “will,” “intend,” “plan,” “believe,” “target,” “forecast” (including the negative or variations thereof) or similar terminology used in connection with any discussion of future plans, actions or events generally identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding macroeconomic conditions, delivered product costs, demand, inflation, currency translation, and our financial and business performance and prospects, including sales, earnings, special charges, margins, interest expense, and productivity. These statements are based on the current expectations of management of the company. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this news release. In particular, the ultimate results of any restructuring initiative depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness.
Additional risks and uncertainties that may affect operating results and business performance are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk, reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the
Non-GAAP Financial Information
This news release and certain of the accompanying tables include financial measures that have not been calculated in accordance with accounting principles generally accepted in the
These non-GAAP financial measures include:
- fixed currency sales
- organic sales, formerly known as acquisition adjusted fixed currency sales
- adjusted cost of sales
- adjusted gross profit
- adjusted gross margin
- fixed currency operating income
- adjusted operating income
- adjusted fixed currency operating income
- adjusted fixed currency operating income margin
- organic operating income, formerly known as acquisition adjusted fixed currency operating income
- organic operating income margin, formerly known as acquisition adjusted fixed currency operating income margin
- adjusted tax rate
- adjusted net income attributable to Ecolab
- adjusted diluted earnings per share
We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.
Our non-GAAP financial measures for adjusted cost of sales, adjusted gross margin, adjusted gross profit and adjusted operating income exclude the impact of special (gains) and charges and our non-GAAP financial measures for adjusted tax rate, adjusted net income attributable to Ecolab and adjusted diluted earnings per share further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.
We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this release are based on translation into
Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to the Company’s reportable segments.
Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude the impact of special (gains) and charges, the results of our acquired businesses from the first twelve months post acquisition and the results of divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months and for a small set of products with limited suppliers over the next few years. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.
These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in this news release. Reconciliations of our non-GAAP measures are included in the following "Supplemental Non-GAAP Reconciliations" and “Supplemental Diluted Earnings per Share Information” tables included in this news release.
We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this news release) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information.
(ECL-E)
ECOLAB INC. CONSOLIDATED STATEMENTS OF INCOME (unaudited) |
|||||||||||
|
|
|
|
|
|
|
|||||
|
|
First Quarter Ended |
|
|
|||||||
|
|
March 31 |
|
% |
|||||||
(millions, except per share) |
|
|
2023 |
|
|
|
2022 |
|
|
Change |
|
|
|
|
|
|
|
|
|||||
Product and equipment sales |
|
$ |
2,876.3 |
|
|
$ |
2,624.1 |
|
|
|
|
Service and lease sales |
|
|
695.3 |
|
|
|
642.6 |
|
|
|
|
Net sales |
|
|
3,571.6 |
|
|
|
3,266.7 |
|
|
9 |
% |
Product and equipment cost of sales |
|
|
1,798.3 |
|
|
|
1,695.6 |
|
|
|
|
Service and lease cost of sales |
|
|
406.9 |
|
|
|
377.8 |
|
|
|
|
Cost of sales (1) |
|
|
2,205.2 |
|
|
|
2,073.4 |
|
|
6 |
% |
Selling, general and administrative expenses |
|
|
990.3 |
|
|
|
914.7 |
|
|
8 |
% |
Special (gains) and charges (1) |
|
|
24.5 |
|
|
|
24.1 |
|
|
|
|
Operating income |
|
|
351.6 |
|
|
|
254.5 |
|
|
38 |
% |
Other (income) expense |
|
|
(13.1 |
) |
|
|
(18.8 |
) |
|
(30 |
)% |
Interest expense, net |
|
|
74.2 |
|
|
|
53.0 |
|
|
40 |
% |
Income before income taxes |
|
|
290.5 |
|
|
|
220.3 |
|
|
32 |
% |
Provision for income taxes |
|
|
52.4 |
|
|
|
45.6 |
|
|
15 |
% |
Net income including noncontrolling interest |
|
|
238.1 |
|
|
|
174.7 |
|
|
36 |
% |
Net income attributable to noncontrolling interest |
|
|
4.7 |
|
|
|
2.8 |
|
|
|
|
Net income attributable to Ecolab |
|
$ |
233.4 |
|
|
$ |
171.9 |
|
|
36 |
% |
|
|
|
|
|
|
|
|||||
Earnings attributable to Ecolab per common share |
|
|
|
|
|||||||
Basic |
|
$ |
0.82 |
|
|
$ |
0.60 |
|
|
37 |
% |
Diluted |
|
$ |
0.82 |
|
|
$ |
0.60 |
|
|
37 |
% |
|
|
|
|
|
|
|
|||||
Weighted-average common shares outstanding |
|
|
|
|
|||||||
Basic |
|
|
284.6 |
|
|
|
286.2 |
|
|
(1 |
)% |
Diluted |
|
|
285.9 |
|
|
|
288.1 |
|
|
(1 |
)% |
|
|
|
|
|
|
|
|||||
(1) Cost of sales and Special (gains) and charges in the Consolidated Statement of Income above include the following: |
|||||||||||
|
|
|
|
|
|
|
|||||
|
|
First Quarter Ended |
|
|
|||||||
|
|
March 31 |
|
|
|||||||
(millions) |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of sales |
|
|
|
|
|
|
|||||
Restructuring activities |
|
$ |
3.2 |
|
|
$ |
2.6 |
|
|
|
|
Acquisition and integration activities |
|
|
- |
|
|
|
27.6 |
|
|
|
|
COVID-19 activities, net |
|
|
- |
|
|
|
16.3 |
|
|
|
|
|
|
|
- |
|
|
|
6.4 |
|
|
|
|
Subtotal (a) |
|
|
3.2 |
|
|
|
52.9 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Special (gains) and charges |
|
|
|
|
|
|
|||||
Restructuring activities |
|
|
12.6 |
|
|
|
0.8 |
|
|
|
|
Acquisition and integration activities |
|
|
5.0 |
|
|
|
7.5 |
|
|
|
|
COVID-19 activities, net |
|
|
- |
|
|
|
1.5 |
|
|
|
|
|
|
|
0.3 |
|
|
|
11.6 |
|
|
|
|
Other |
|
|
6.6 |
|
|
|
2.7 |
|
|
|
|
Subtotal |
|
|
24.5 |
|
|
|
24.1 |
|
|
|
|
|
|
|
|
|
|
|
|||||
Total special (gains) and charges |
|
$ |
27.7 |
|
|
$ |
77.0 |
|
|
|
a) Special charges of |
ECOLAB INC. REPORTABLE SEGMENT INFORMATION (unaudited) |
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
First Quarter Ended March 31 |
|||||||||||||||||||||
|
|
Fixed Currency Rates |
|
Public Currency Rates |
|||||||||||||||||||
|
|
|
|
|
|
% |
|
|
|
|
|
% |
|||||||||||
(millions) |
|
|
2023 |
|
|
|
2022 |
|
|
Change |
|
|
2023 |
|
|
|
2022 |
|
|
Change |
|||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Global Industrial |
|
$ |
1,699.3 |
|
|
$ |
1,511.4 |
|
|
12 |
|
% |
|
$ |
1,709.4 |
|
|
$ |
1,565.7 |
|
|
9 |
% |
Global Institutional & Specialty |
|
|
1,126.6 |
|
|
|
991.3 |
|
|
14 |
|
% |
|
|
1,128.8 |
|
|
|
1,009.4 |
|
|
12 |
% |
Global Healthcare & Life Sciences |
|
|
378.6 |
|
|
|
348.2 |
|
|
9 |
|
% |
|
|
379.7 |
|
|
|
362.8 |
|
|
5 |
% |
Other |
|
|
329.3 |
|
|
|
286.8 |
|
|
15 |
|
% |
|
|
330.0 |
|
|
|
294.0 |
|
|
12 |
% |
Corporate |
|
|
23.6 |
|
|
|
34.6 |
|
|
(32 |
) |
% |
|
|
23.7 |
|
|
|
34.8 |
|
|
(32 |
)% |
Subtotal at fixed currency rates |
|
|
3,557.4 |
|
|
|
3,172.3 |
|
|
12 |
|
% |
|
|
3,571.6 |
|
|
|
3,266.7 |
|
|
9 |
% |
Currency impact |
|
|
14.2 |
|
|
|
94.4 |
|
|
* |
|
|
|
- |
|
|
|
- |
|
|
* |
||
Consolidated reported GAAP net sales |
|
$ |
3,571.6 |
|
|
$ |
3,266.7 |
|
|
9 |
|
% |
|
$ |
3,571.6 |
|
|
$ |
3,266.7 |
|
|
9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating Income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Global Industrial |
|
$ |
215.6 |
|
|
$ |
179.9 |
|
|
20 |
|
% |
|
$ |
217.7 |
|
|
$ |
191.1 |
|
|
14 |
% |
Global Institutional & Specialty |
|
|
125.7 |
|
|
|
108.6 |
|
|
16 |
|
% |
|
|
125.9 |
|
|
|
110.9 |
|
|
14 |
% |
Global Healthcare & Life Sciences |
|
|
35.0 |
|
|
|
41.9 |
|
|
(16 |
) |
% |
|
|
35.2 |
|
|
|
44.3 |
|
|
(21 |
)% |
Other |
|
|
50.1 |
|
|
|
37.1 |
|
|
35 |
|
% |
|
|
50.2 |
|
|
|
37.9 |
|
|
32 |
% |
Corporate |
|
|
(77.4 |
) |
|
|
(129.0 |
) |
|
* |
|
|
|
(77.4 |
) |
|
|
(129.7 |
) |
|
* |
||
Subtotal at fixed currency rates |
|
|
349.0 |
|
|
|
238.5 |
|
|
46 |
|
% |
|
|
351.6 |
|
|
|
254.5 |
|
|
38 |
% |
Currency impact |
|
|
2.6 |
|
|
|
16.0 |
|
|
* |
|
|
|
- |
|
|
|
- |
|
|
* |
||
Consolidated reported GAAP operating income |
|
$ |
351.6 |
|
|
$ |
254.5 |
|
|
38 |
|
% |
|
$ |
351.6 |
|
|
$ |
254.5 |
|
|
38 |
% |
* Not meaningful. |
|
|
|
|
|
|
|
|
|
|
|
|
|
As shown in the “Fixed Currency Rates” tables above, we evaluate the performance of our international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Amounts shown in the “Public Currency Rates” tables above reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and are provided for informational purposes. The difference between the fixed currency exchange rates and the public currency exchange rates is reported as “Currency impact” in the “Fixed Currency Rates” tables above.
The Corporate segment includes amortization from the Nalco and Purolite transactions intangible assets. The Corporate segment also includes special (gains) and charges reported on the Consolidated Statement of Income.
ECOLAB INC. CONSOLIDATED BALANCE SHEETS (unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
March 31 |
|
December |
March 31 |
|||||||||||
(millions) |
2023 |
|
2022 |
2022 |
|||||||||||
Assets |
|
|
|
|
|
|
|
|
|||||||
Current assets |
|
|
|
|
|
|
|
|
|||||||
Cash and cash equivalents |
$ |
419.4 |
|
|
|
$ |
598.6 |
|
|
|
$ |
99.4 |
|
|
|
Accounts receivable, net |
|
2,667.8 |
|
|
|
|
2,698.1 |
|
|
|
|
2,508.2 |
|
|
|
Inventories |
|
1,727.3 |
|
|
|
|
1,792.8 |
|
|
|
|
1,589.9 |
|
|
|
Other current assets |
|
458.3 |
|
|
|
|
404.7 |
|
|
|
|
407.0 |
|
|
|
Total current assets |
|
5,272.8 |
|
|
|
|
5,494.2 |
|
|
|
|
4,604.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Property, plant and equipment, net |
|
3,312.7 |
|
|
|
|
3,293.4 |
|
|
|
|
3,285.7 |
|
|
|
Goodwill |
|
8,062.2 |
|
|
|
|
8,012.7 |
|
|
|
|
8,081.0 |
|
|
|
Other intangible assets, net |
|
3,616.8 |
|
|
|
|
3,680.7 |
|
|
|
|
4,138.3 |
|
|
|
Operating lease assets |
|
430.6 |
|
|
|
|
448.2 |
|
|
|
|
385.8 |
|
|
|
Other assets |
|
556.4 |
|
|
|
|
535.1 |
|
|
|
|
571.9 |
|
|
|
Total assets |
$ |
21,251.5 |
|
|
|
$ |
21,464.3 |
|
|
|
$ |
21,067.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Liabilities and Equity |
|
|
|
|
|
|
|
|
|||||||
Current liabilities |
|
|
|
|
|
|
|
|
|||||||
Short-term debt |
$ |
1,118.1 |
|
|
|
$ |
505.1 |
|
|
|
$ |
493.1 |
|
|
|
Accounts payable |
|
1,469.9 |
|
|
|
|
1,728.2 |
|
|
|
|
1,423.9 |
|
|
|
Compensation and benefits |
|
450.2 |
|
|
|
|
493.6 |
|
|
|
|
469.6 |
|
|
|
Income taxes |
|
171.6 |
|
|
|
|
197.6 |
|
|
|
|
108.6 |
|
|
|
Other current liabilities |
|
1,279.8 |
|
|
|
|
1,285.9 |
|
|
|
|
1,136.1 |
|
|
|
Total current liabilities |
|
4,489.6 |
|
|
|
|
4,210.4 |
|
|
|
|
3,631.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Long-term debt |
|
7,521.7 |
|
|
|
|
8,075.3 |
|
|
|
|
8,267.2 |
|
|
|
Pension and postretirement benefits |
|
665.5 |
|
|
|
|
670.3 |
|
|
|
|
874.5 |
|
|
|
Deferred income taxes |
|
496.1 |
|
|
|
|
505.6 |
|
|
|
|
619.2 |
|
|
|
Operating lease liabilities |
|
323.4 |
|
|
|
|
337.8 |
|
|
|
|
275.2 |
|
|
|
Other liabilities |
|
390.2 |
|
|
|
|
406.3 |
|
|
|
|
294.7 |
|
|
|
Total liabilities |
|
13,886.5 |
|
|
|
|
14,205.7 |
|
|
|
|
13,962.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Equity |
|
|
|
|
|
|
|
|
|||||||
Common stock |
|
365.0 |
|
|
|
|
364.7 |
|
|
|
|
364.5 |
|
|
|
Additional paid-in capital |
|
6,626.5 |
|
|
|
|
6,580.2 |
|
|
|
|
6,501.5 |
|
|
|
Retained earnings |
|
9,401.3 |
|
|
|
|
9,318.8 |
|
|
|
|
8,840.4 |
|
|
|
Accumulated other comprehensive loss |
|
(1,737.2 |
) |
|
|
|
(1,726.6 |
) |
|
|
|
(1,563.6 |
) |
|
|
Treasury stock |
|
(7,311.4 |
) |
|
|
|
(7,301.0 |
) |
|
|
|
(7,061.2 |
) |
|
|
Total Ecolab shareholders’ equity |
|
7,344.2 |
|
|
|
|
7,236.1 |
|
|
|
|
7,081.6 |
|
|
|
Noncontrolling interest |
|
20.8 |
|
|
|
|
22.5 |
|
|
|
|
23.5 |
|
|
|
Total equity |
|
7,365.0 |
|
|
|
|
7,258.6 |
|
|
|
|
7,105.1 |
|
|
|
Total liabilities and equity |
$ |
21,251.5 |
|
|
|
$ |
21,464.3 |
|
|
|
$ |
21,067.2 |
|
|
ECOLAB INC. SUPPLEMENTAL NON-GAAP RECONCILIATIONS (unaudited) |
|||||||||
|
|
|
|
|
|
||||
|
|
First Quarter Ended |
|
||||||
|
|
March 31 |
|
||||||
(millions, except percent and per share) |
|
2023 |
|
2022 |
|
||||
|
|
|
|
|
|
||||
Net sales |
|
|
|
|
|
||||
Reported GAAP net sales |
|
$ |
3,571.6 |
|
|
$ |
3,266.7 |
|
|
Effect of foreign currency translation |
|
|
(14.2 |
) |
|
|
(94.4 |
) |
|
Non-GAAP fixed currency sales |
|
|
3,557.4 |
|
|
|
3,172.3 |
|
|
Effect of acquisitions and divestitures |
|
|
(23.6 |
) |
|
|
(34.6 |
) |
|
Non-GAAP organic sales |
|
$ |
3,533.8 |
|
|
$ |
3,137.7 |
|
|
|
|
|
|
|
|
||||
Cost of sales |
|
|
|
|
|
||||
Reported GAAP cost of sales |
|
$ |
2,205.2 |
|
|
$ |
2,073.4 |
|
|
Special (gains) and charges |
|
|
3.2 |
|
|
|
52.9 |
|
|
Non-GAAP adjusted cost of sales |
|
$ |
2,202.0 |
|
|
$ |
2,020.5 |
|
|
|
|
|
|
|
|
||||
Gross profit |
|
|
|
|
|
||||
Reported GAAP gross profit |
|
$ |
1,366.4 |
|
|
$ |
1,193.3 |
|
|
Special (gains) and charges |
|
|
3.2 |
|
|
|
52.9 |
|
|
Non-GAAP adjusted gross profit |
|
$ |
1,369.6 |
|
|
$ |
1,246.2 |
|
|
|
|
|
|
|
|
||||
Gross margin |
|
|
|
|
|
||||
Reported GAAP gross margin |
|
|
38.3 |
% |
|
|
36.5 |
% |
|
Non-GAAP adjusted gross margin |
|
|
38.3 |
% |
|
|
38.1 |
% |
|
|
|
|
|
|
|
||||
Operating income |
|
|
|
|
|
||||
Reported GAAP operating income |
|
$ |
351.6 |
|
|
$ |
254.5 |
|
|
Effect of foreign currency translation |
|
|
(2.6 |
) |
|
|
(16.0 |
) |
|
Non-GAAP fixed currency operating income |
|
|
349.0 |
|
|
|
238.5 |
|
|
Special (gains) and charges at fixed currency rates |
|
|
27.6 |
|
|
|
77.0 |
|
|
Non-GAAP adjusted fixed currency operating income |
|
|
376.6 |
|
|
|
315.5 |
|
|
Effect of acquisitions and divestitures |
|
|
(0.5 |
) |
|
|
- |
|
|
Non-GAAP organic operating income |
|
$ |
376.1 |
|
|
$ |
315.5 |
|
|
|
|
|
|
|
|
||||
Operating income margin |
|
|
|
|
|
||||
Reported GAAP operating income margin |
|
|
9.8 |
% |
|
|
7.8 |
% |
|
Non-GAAP adjusted fixed currency operating income margin |
|
|
10.6 |
% |
|
|
9.9 |
% |
|
Non-GAAP organic operating income margin |
|
|
10.6 |
% |
|
|
10.1 |
% |
|
|
|
|
|
|
|
ECOLAB INC. SUPPLEMENTAL NON-GAAP RECONCILIATIONS (unaudited) |
|||||||||
|
|
|
|
|
|
||||
|
|
First Quarter Ended |
|
||||||
|
|
March 31 |
|
||||||
(millions, except percent and per share) |
|
2023 |
|
2022 |
|
||||
|
|
|
|
|
|
||||
Net Income attributable to Ecolab |
|
|
|
|
|
||||
Reported GAAP net income attributable to Ecolab |
|
$ |
233.4 |
|
|
$ |
171.9 |
|
|
Special (gains) and charges, after tax |
|
|
21.1 |
|
|
|
63.6 |
|
|
Discrete tax net expense (benefit) |
|
|
(4.0 |
) |
|
|
1.0 |
|
|
Non-GAAP adjusted net income attributable to Ecolab |
|
$ |
250.5 |
|
|
$ |
236.5 |
|
|
|
|
|
|
|
|
||||
Diluted EPS attributable to Ecolab |
|
|
|
|
|
||||
Reported GAAP diluted EPS |
|
$ |
0.82 |
|
|
$ |
0.60 |
|
|
Special (gains) and charges, after tax |
|
|
0.07 |
|
|
|
0.22 |
|
|
Discrete tax net expense (benefit) |
|
|
(0.01 |
) |
|
|
- |
|
|
Non-GAAP adjusted diluted EPS |
|
$ |
0.88 |
|
|
$ |
0.82 |
|
|
|
|
|
|
|
|
||||
Provision for Income Taxes |
|
|
|
|
|
||||
Reported GAAP tax rate |
|
|
18.0 |
% |
|
|
20.7 |
% |
|
Special gains and charges |
|
|
0.5 |
|
|
|
(0.9 |
) |
|
Discrete tax items |
|
|
1.3 |
|
|
|
(0.3 |
) |
|
Non-GAAP adjusted tax rate |
|
|
19.8 |
% |
|
|
19.5 |
% |
|
ECOLAB INC. SUPPLEMENTAL NON-GAAP RECONCILIATIONS (unaudited) |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
First Quarter Ended March 31 |
||||||||||||||||||||||
|
|
2023 |
|
|
2022 |
|
||||||||||||||||||
(millions) |
|
Fixed Currency |
|
Impact of Acquisitions and Divestitures |
|
Organic |
|
Fixed Currency |
|
Impact of Acquisitions and Divestitures |
|
Organic |
||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Global Industrial |
|
$ |
1,699.3 |
|
|
$ |
- |
|
|
$ |
1,699.3 |
|
|
$ |
1,511.4 |
|
|
$ |
- |
|
|
$ |
1,511.4 |
|
Global Institutional & Specialty |
|
|
1,126.6 |
|
|
|
- |
|
|
|
1,126.6 |
|
|
|
991.3 |
|
|
|
- |
|
|
|
991.3 |
|
Global Healthcare & Life Sciences |
|
|
378.6 |
|
|
|
- |
|
|
|
378.6 |
|
|
|
348.2 |
|
|
|
- |
|
|
|
348.2 |
|
Other |
|
|
329.3 |
|
|
|
- |
|
|
|
329.3 |
|
|
|
286.8 |
|
|
|
- |
|
|
|
286.8 |
|
Corporate |
|
|
23.6 |
|
|
|
(23.6 |
) |
|
|
- |
|
|
|
34.6 |
|
|
|
(34.6 |
) |
|
|
- |
|
Subtotal at fixed currency rates |
|
|
3,557.4 |
|
|
|
(23.6 |
) |
|
|
3,533.8 |
|
|
|
3,172.3 |
|
|
|
(34.6 |
) |
|
|
3,137.7 |
|
Currency impact |
|
|
14.2 |
|
|
|
|
|
|
|
94.4 |
|
|
|
|
|
||||||||
Consolidated reported GAAP net sales |
|
$ |
3,571.6 |
|
|
|
|
|
|
$ |
3,266.7 |
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating Income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Global Industrial |
|
$ |
215.6 |
|
|
$ |
- |
|
|
$ |
215.6 |
|
|
$ |
179.9 |
|
|
$ |
- |
|
|
$ |
179.9 |
|
Global Institutional & Specialty |
|
|
125.7 |
|
|
|
- |
|
|
|
125.7 |
|
|
|
108.6 |
|
|
|
- |
|
|
|
108.6 |
|
Global Healthcare & Life Sciences |
|
|
35.0 |
|
|
|
- |
|
|
|
35.0 |
|
|
|
41.9 |
|
|
|
- |
|
|
|
41.9 |
|
Other |
|
|
50.1 |
|
|
|
- |
|
|
|
50.1 |
|
|
|
37.1 |
|
|
|
- |
|
|
|
37.1 |
|
Corporate |
|
|
(49.8 |
) |
|
|
(0.5 |
) |
|
|
(50.3 |
) |
|
|
(52.0 |
) |
|
|
- |
|
|
|
(52.0 |
) |
Subtotal at fixed currency rates |
|
|
376.6 |
|
|
|
(0.5 |
) |
|
|
376.1 |
|
|
|
315.5 |
|
|
|
- |
|
|
|
315.5 |
|
Special (gains) and charges at fixed currency rates |
|
|
27.6 |
|
|
|
|
|
|
|
77.0 |
|
|
|
|
|
||||||||
Reported OI at fixed currency rates |
|
|
349.0 |
|
|
|
|
|
|
|
238.5 |
|
|
|
|
|
||||||||
Currency impact |
|
|
2.6 |
|
|
|
|
|
|
|
16.0 |
|
|
|
|
|
||||||||
Consolidated reported GAAP operating income |
|
$ |
351.6 |
|
|
|
|
|
|
$ |
254.5 |
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
ECOLAB INC. |
SUPPLEMENTAL DILUTED EARNINGS PER SHARE INFORMATION |
(unaudited) |
|
|
The table below provides a reconciliation of diluted earnings per share, as reported, to the non-GAAP measure of adjusted diluted earnings per share. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
First |
|
Second |
|
Six |
|
Third |
|
Nine |
|
Fourth |
|
|
|
|||||||||||
|
|
Quarter |
|
Quarter |
|
Months |
|
Quarter |
|
Months |
|
Quarter |
|
Year |
|
|||||||||||
|
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
|||||||||||
|
|
Mar. 31 |
|
June 30 |
|
June 30 |
|
Sept. 30 |
|
Sept. 30 |
|
Dec. 31 |
|
Dec. 31 |
|
|||||||||||
|
|
|
2022 |
|
|
2022 |
|
|
2022 |
|
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
Diluted earnings per share, as reported ( |
|
$ |
0.60 |
|
$ |
1.08 |
|
$ |
1.67 |
|
$ |
1.21 |
|
|
$ |
2.88 |
|
|
$ |
0.93 |
|
|
$ |
3.81 |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Special (gains) and charges (1) |
|
|
0.22 |
|
|
0.01 |
|
|
0.23 |
|
|
0.14 |
|
|
|
0.37 |
|
|
|
0.35 |
|
|
|
0.72 |
|
|
Discrete tax expense (benefits) (2) |
|
|
0.00 |
|
|
0.01 |
|
|
0.02 |
|
|
(0.05 |
) |
|
|
(0.03 |
) |
|
|
(0.01 |
) |
|
|
(0.04 |
) |
|
Adjusted diluted earnings per share (Non-GAAP) |
|
$ |
0.82 |
|
$ |
1.10 |
|
$ |
1.92 |
|
$ |
1.30 |
|
|
$ |
3.22 |
|
|
$ |
1.27 |
|
|
$ |
4.49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
First |
|
Second |
|
Six |
|
Third |
|
Nine |
|
Fourth |
|
|
|
||||||||
|
|
Quarter |
|
Quarter |
|
Months |
|
Quarter |
|
Months |
|
Quarter |
|
Year |
|
||||||||
|
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
Ended |
|
||||||||
|
|
Mar. 31 |
|
June 30 |
|
June 30 |
|
Sept. 30 |
|
Sept. 30 |
|
Dec. 31 |
|
Dec. 31 |
|
||||||||
|
|
|
2023 |
|
|
|
2023 |
|
|
2023 |
|
|
2023 |
|
|
2023 |
|
|
2023 |
|
|
2023 |
|
Diluted earnings per share, as reported ( |
|
$ |
0.82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Special (gains) and charges (3) |
|
|
0.07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Discrete tax expense (benefits) (4) |
|
|
(0.01 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted diluted earnings per share (Non-GAAP) |
|
$ |
0.88 |
|
|
$ |
0.00 |
|
$ |
0.00 |
|
$ |
0.00 |
|
$ |
0.00 |
|
$ |
0.00 |
|
$ |
0.00 |
|
Per share amounts do not necessarily sum due to changes in shares outstanding and rounding. |
|
(1) Special (gains) and charges for 2022 includes charges of |
|
(2) Discrete tax expenses (benefits) for 2022 includes |
|
(3) Special (gains) and charges for 2023 includes charges of |
|
(4) Discrete tax (benefits) for 2023 includes |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005759/en/
Investor Contact:
Andrew Hedberg (651) 250-2185
Cairn Clark (651) 250-2291
Media Contact:
Nigel Glennie (651) 250-2576
Source: Ecolab Inc.